London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Optimism is not what I invest on. This drug like many has potential, not doubting that one bit.
But the facts are it needs cash, approx 7-10m will be a good start. If they sell the gold shares that would be great as there not in the companies business interest anymore. But this is up to the directors not us.
The alternative is serious dilution at a large discount, like all small aim companies, including FUM.
Just look at FUM and see its price action over the past couple years. 20p, £1, 50p, 5p, now 45p. It went down to 5p on funding lol. OVB will not be much different in its journey.
FUM are now at the last hurdles with Ph3 trails, which could go anyway let’s be honest. But until it’s results come out in Nov/Dec it will be on an upward trend, like it has been for past 6 months, with small retraces on the way.
OVB will get there as well, but funding, dilution, probable phase2b trails needed for EU & US before they will get to even start phase 3 trails for eu/us. Remember EU/US are the main markets!
This may continue to rise, no one can guess where it will go or not. But the concerns above need to be addressed as well.
Just hoping a share goes up for it future potential is not the best investing method, especially when that potential is 3 possibly years away and many hurdles along the way.
Much more optimistic about FUM, happily!
Yesman,
You're not really an optimist are you?
How difficult do you think it would be to borrow or raise capital against the polymetal shares, or even to sell some of them?
Agreed it looks interesting, but if they don’t sell the gold cash is needed imminently to do any trials in eu/us no?
When these aim bios raise cash it’s normally at a significantly lower price and a significant dilution. Once the funding question is out of the way and they get go ahead for trails, then it will feel safer.
Agreed it looks interesting, but if they don’t sell the gold cash is needed imminently to do any trials in eu/us no?
Thanks. Hoping for a retrace as this rise has been astonishing this morning. GLAHs inc my small investment!!!!!
Ovoca Bio used to be called Ovoca Gold. The Poly shares were acquired as part of its previous life in a deal. Ovoca also held a mine that was mothballed and had some claims on loans that never came to anything from memory. 8 or 9 months ago I think, news was imminent with most thinking that the poly shares would be sold and capital returned to shareholders and so the price drifted up but well short of the NAV value...but instead they bought into IVIX and became a pharma. It's definitely a random backstory.
Positive news will multibag this
I do think a buy out of the Patent is diffidently going to happen here. So much progress has been achieved to get to this stage.
The question is how much is this worth ? We know R & D cost many £10's M's and years of companies time and effort.
£25-£50M ? would still be very cheap considering the scale and sole patent of this product.
First stop 30p
Also looked this morning.zgood questions 're pls ing in particular.Would hate to get spiked!!! Increase 100% in short space of time.Need to read up more on poly!!! Such a strange holding for a pharma!!!!!
They’re looking for a similar sum imho - that’s a 1500 bagger
As they point out themselves on the website
Only one pharmaceutical treatment, Addyi (flibanserin, antidepressant with selective action at serotonin 5-HT receptors), is marketed in the US for HSDD. Flibanserin efficacy in large US-based clinical studies was statistically significant over placebo, but demonstrated concomitant safety problems, such as risk of severe hypotension and syncope when taken together with alcohol or even Addyi alone, or Central Nervous System (CNS) depression (e.g., somnolence, sedation) with Addyi alone. Other common side effects included dizziness, somnolence, nausea, fatigue, insomnia, and dry mouth. In October 2015, Valeant Pharmaceticals acquired Sprout Pharmaceuticals, the producer of Addyi, for an aggregate purchase price of $1.45 billion, which included cash plus contingent consideration. Subsequently, in December 2017, Valeant completed the sale of Sprout to a buyer affiliated with certain former shareholders of Sprout, in exchange for a 6% royalty on global sales of Addyi beginning June 2019. Valeant noted that the sale of Sprout provided it with the opportunity to divest a business that was not core to its objectives, while also allowing it to resolve an ongoing legal matter between it and former shareholders of Sprout relating to compliance with certain contractual terms of the 2015 acquisition agreement with respect to the use of certain diligent efforts by Valeant to develop and commercialize Addyi.
There’s also the matter of the £14m+ worth of POLY shares they hold. Once they get this into one market, which I understand is imminent (they’ve already appointed the CMOs and packaging manufacturer) they’ll get bought out.
Totally agree. It's still way undervalued with so much potential. News soon hopefully
Of course they will require mo et at some stage but now the float is tightly held by directors. Once a phase 3 is done as longs as its approved by others then its a go. Think what would happen if everyone wanted a drugs company to repeat all trials. Nothing would get to market
Just recently came across this, have some questions if anyone can help:
1) The phase 3 that was completed was only for Russia right? Therefore to get into the EU & US markets they will not only have to complete 2x phase 3 studies under EU/ US regulation, but it likely they will have to complete a phase2b first? Please correct me if I am wrong.
1) I see they own a large chunk of share in a gold company, however actual cash looks like they only actually have 1-2m? If that’s the case there will be a big raise coming/ dilution. 2m is no where near enough to run a phase 2 and then 2x phase 3 trials for for EU/US. Obviously the gold stock is worth a good amount which would help significantly, but is there any plan to sell it? I didn’t see anything?
While the drug seems promising, unless my initial understanding on the above is incorrect, it’s quite likely that there will be a large raise, or two, over the coming years, which means significant dilution. Also a phase 2b and 2x phase 3 trails will take years from now.
FYI 2 x phase 3 trails for EU/ US regulators is quite normal.
Any info will be much appreciated.